Icosavax Provides Corporate Update and Anticipated Milestones for 2022
January 07, 2022 08:00 ET
|
Icosavax, Inc.
SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Appoints Dr. John Shiver to Board of Directors
January 05, 2022 08:00 ET
|
Icosavax, Inc.
SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021 16:05 ET
|
Icosavax, Inc.
- Initiated a Phase 1/1b clinical trial for IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Completed...
Icosavax to Participate in Upcoming Investor Conferences
November 11, 2021 16:22 ET
|
Icosavax, Inc.
SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update
September 13, 2021 16:05 ET
|
Icosavax, Inc.
- Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain - - Initiated a Phase 1/1b clinical trial for IVX-121, a VLP...
Icosavax Appoints Elizabeth Bekiroğlu to General Counsel
September 10, 2021 08:00 ET
|
Icosavax, Inc.
SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus
September 09, 2021 08:00 ET
|
Icosavax, Inc.
SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Mourns Sudden Passing of Tadataka Yamada, M.D. Chairman of the Company’s Board of Directors
August 05, 2021 08:00 ET
|
Icosavax, Inc.
SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 02, 2021 16:01 ET
|
Icosavax, Inc.
SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...